These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 26640968)

  • 21. Inside HDAC with HDAC inhibitors.
    Bertrand P
    Eur J Med Chem; 2010 Jun; 45(6):2095-116. PubMed ID: 20223566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic potential of selective histone deacetylase 3 inhibition.
    Zhang L; Chen Y; Jiang Q; Song W; Zhang L
    Eur J Med Chem; 2019 Jan; 162():534-542. PubMed ID: 30472601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of potential isoform-selective histone deacetylase inhibitors for cancer therapy: a combined approach of structure-based virtual screening, ADMET prediction and molecular dynamics simulation assay.
    Uba AI; Yelekçi K
    J Biomol Struct Dyn; 2018 Sep; 36(12):3231-3245. PubMed ID: 28938863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylases: structural determinants of inhibitor selectivity.
    Micelli C; Rastelli G
    Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo.
    Weichert W; Röske A; Niesporek S; Noske A; Buckendahl AC; Dietel M; Gekeler V; Boehm M; Beckers T; Denkert C
    Clin Cancer Res; 2008 Mar; 14(6):1669-77. PubMed ID: 18347167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Azetidinones as zinc-binding groups to design selective HDAC8 inhibitors.
    Galletti P; Quintavalla A; Ventrici C; Giannini G; Cabri W; Penco S; Gallo G; Vincenti S; Giacomini D
    ChemMedChem; 2009 Dec; 4(12):1991-2001. PubMed ID: 19821480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.
    Thaler F; Mercurio C
    ChemMedChem; 2014 Mar; 9(3):523-6. PubMed ID: 24730063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis.
    Takebe M; Oishi H; Taguchi K; Aoki Y; Takashina M; Tomita K; Yokoo H; Takano Y; Yamazaki M; Hattori Y
    J Surg Res; 2014 Apr; 187(2):559-70. PubMed ID: 24290430
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.
    Marson CM; Matthews CJ; Atkinson SJ; Lamadema N; Thomas NS
    J Med Chem; 2015 Sep; 58(17):6803-18. PubMed ID: 26287310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective role of sodium butyrate, a HDAC inhibitor on beta-cell proliferation, function and glucose homeostasis through modulation of p38/ERK MAPK and apoptotic pathways: study in juvenile diabetic rat.
    Khan S; Jena GB
    Chem Biol Interact; 2014 Apr; 213():1-12. PubMed ID: 24530320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Environment-sensitive fluorescent inhibitors of histone deacetylase.
    Zhou X; Dong G; Song T; Wang G; Li Z; Qin X; Du L; Li M
    Bioorg Med Chem Lett; 2020 Jun; 30(11):127128. PubMed ID: 32247729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects.
    Trivedi P; Adhikari N; Amin SA; Jha T; Ghosh B
    Eur J Pharm Sci; 2018 Nov; 124():165-181. PubMed ID: 30171982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Energy-optimised pharmacophore approach to identify potential hotspots during inhibition of Class II HDAC isoforms.
    Ganai SA; Shanmugam K; Mahadevan V
    J Biomol Struct Dyn; 2015; 33(2):374-87. PubMed ID: 24460542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress inhibition.
    Khan S; Komarya SK; Jena G
    Epigenomics; 2017 May; 9(5):711-720. PubMed ID: 28470097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).
    Methot JL; Chakravarty PK; Chenard M; Close J; Cruz JC; Dahlberg WK; Fleming J; Hamblett CL; Hamill JE; Harrington P; Harsch A; Heidebrecht R; Hughes B; Jung J; Kenific CM; Kral AM; Meinke PT; Middleton RE; Ozerova N; Sloman DL; Stanton MG; Szewczak AA; Tyagarajan S; Witter DJ; Secrist JP; Miller TA
    Bioorg Med Chem Lett; 2008 Feb; 18(3):973-8. PubMed ID: 18182289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis and preliminary bioactivity studies of 1,2-dihydrobenzo[d]isothiazol-3-one-1,1-dioxide hydroxamic acid derivatives as novel histone deacetylase inhibitors.
    Han L; Wang L; Hou X; Fu H; Song W; Tang W; Fang H
    Bioorg Med Chem; 2014 Mar; 22(5):1529-38. PubMed ID: 24525003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
    Koppel I; Timmusk T
    Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting class I histone deacetylases in cancer therapy.
    Delcuve GP; Khan DH; Davie JR
    Expert Opin Ther Targets; 2013 Jan; 17(1):29-41. PubMed ID: 23062071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
    McCann J; Ellis M; McGee SL; Aston-Mourney K
    Islets; 2019; 11(5):112-118. PubMed ID: 31112063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intrinsic Dynamics of the Binding Rail and Its Allosteric Effect in the Class I Histone Deacetylases.
    Zhou J; Huang Y; Cheng C; Wang K; Wu R
    J Chem Inf Model; 2017 Sep; 57(9):2309-2320. PubMed ID: 28805377
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.